title: [Therapeutic difference by TAE between HCC with HCV-Ab and HBV-Ag].
abstract: Transarterial infusion therapy using adriamycin-Lipiodol emulsion (TAE) was used for 30 patients of HCC with HCV-Ab and 20 patients with HBV-Ag. We compared the tumor effect and prognosis in terms of several clinico-pathological factors. The response rate (PR+MR) after TAE was 43% in HCC patients with HCV-Ab and 30% in those with HBV-Ag. One-year survival rate was 89% in HCC patients with HCV-Ab and 58% in HCC patients with HBV-Ag. Thus, there was a significant difference between the two groups. No definite reasons between two groups influencing tumor effect and prognosis is obviously revealed except for portal vein invasion.
authors.affiliation: Dept. of Internal Medicine, Cancer Institute Hospital.
authors.forename: E
authors.initials: E
authors.lastname: Ninomiya
authors.forename: K
authors.initials: K
authors.lastname: Ohhashi
authors.forename: Y
authors.initials: Y
authors.lastname: Murakami
authors.forename: M
authors.initials: M
authors.lastname: Yamada
authors.forename: K
authors.initials: K
authors.lastname: Takano
authors.forename: T
authors.initials: T
authors.lastname: Nagahama
authors.forename: M
authors.initials: M
authors.lastname: Ogawa
authors.forename: N
authors.initials: N
authors.lastname: Horikoshi
authors.forename: K
authors.initials: K
authors.lastname: Inoue
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000628:therapy*; D004317:Doxorubicin / Q000008:administration & dosage*; D004621:Embolization, Therapeutic; D004655:Emulsions; D005260:Female; D016174:Hepacivirus / Q000276:immunology*; D006499:Hepatic Artery; D006508:Hepatitis Antibodies / Q000032:analysis*; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000276:immunology / Q000628:therapy*; D008297:Male
chemical_list: D004655:Emulsions; D006508:Hepatitis Antibodies; D006514:Hepatitis B Surface Antigens; D007459:Iodized Oil; D004317:Doxorubicin